Cerence EVP, chief admin officer Salinas sells $529,224 in stock

Executive Vice President and Head of Research & Development at Zymeworks Inc., Adam Schayowitz, sold 13,832 shares of the company's common stock on October 9, 2026. The transaction occurred to satisfy tax withholding obligations and other fees associated with the vesting of restricted stock units, as mandated by his RSU grant agreement.

This sale does not indicate that Mr. Schayowitz intended to liquidate any additional shares beyond the necessary amount. The sale price of $25.85 per share was near the current trading price of $25.79 and Zymeworks Inc.'s estimated fair value of $25.88, suggesting the stock was reasonably valued at the time. Zymeworks Inc. shares have achieved a substantial 52% return over the past year, with analysts projecting potential upside, as evidenced by price targets spanning from $32 to $60.

The sale was part of a series of RSU vesting, which granted 37,037 additional shares upon the initial vesting, with this transaction being the first of three equal annual installments. Mr. Schayowitz now holds a total of 23,205 shares of Zymeworks common stock, in addition to owning 74,074 restricted stock units. Zymeworks Inc. recently announced the acquisition of Theravance Biopharma, a move that TD Cowen deemed a significant factor in reinstating their coverage with a Buy rating and a price target of $34.

This acquisition is anticipated to confer substantial commercial, royalty, and research and development value to Zymeworks. The company also received FDA approval for its Ziihera-containing regimens to treat HER2-positive gastroesophageal adenocarcinoma, prompting H.C. Wainwright to raise its price target for the company's stock to $55, maintaining a Buy rating.